Isocitrate Dehydrogenase

In this video, Akriti Jain, MD, discusses whether patients with acute myeloid leukemia with IDH mutations should be treated with IDH inhibitors up front compared to venetoclaxcontaining regimens.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

The addition of venetoclax to azacitidine benefited untreated patients with isocitrate dehydrogenase mutations ineligible for intensive chemotherapy, according to study results presented at the virtual ASH Annual Meeting and Exposition.